Brizal (brinzolamide) eye drops 10mg/ml 5ml Бризаль

Brizal Indications

Brizal® is designed to reduce high intraocular pressure when:

▪ ocular hypertension,

▪ open-angle glaucoma,

▪ as monotherapy in adult patients insensitive to beta-blockers,

▪ in adult patients for whom beta-blockers are contraindicated, or as adjunctive therapy with beta-blockers or prostaglandin analogues.

Contradictions

▪ Hypersensitivity to the active substance or to any other component of the drug.

▪ Hypersensitivity to sulphonamides is known (see also section "Special warnings and precautions for use").

▪ Severe renal failure.

▪ Hyperchloremic acidosis.

Dosage & Administration

For ophthalmic use.

It is recommended to press in the area of ​​the nasolacrimal opening or carefully close the eyelids after instillation. This reduces the systemic absorption of drugs administered to the eye, which reduces the likelihood of systemic side effects.

The vial should be well shaken before use. To prevent contamination of the dropper edge and the contents of the vial, be careful not to touch the eyelids, adjacent or other surfaces with the edge of the dropper vial. Keep the vial tightly closed during storage.

Special groups of patients

Application to the elderly

No dose adjustment is required for elderly patients.

Use in disorders of the liver and kidneys

The use of brinzolamide for the treatment of patients with hepatic insufficiency has not been studied, so the drug is not recommended for the treatment of such patients.

Brinzolamide has not been studied in patients with severe renal impairment (creatinine clearance ® is contraindicated for the treatment of such patients) (see also section "Contraindications").

Children.

Efficacy and safety of Brizal® treatment in patients under 18 years of age have not been established. Existing data on the use of this category of patients are presented in the sections "Features of use" and "Pharmacodynamics". Brizal® is not recommended for children.